Deals, mandates, and milestones from Modulus Biotech.
September 10, 2026
·
Perspective
The value is not in the list of names, it is in the sequence: sorting buyers by which face of your asset each one actually pays for.
Read the full article →
September 9, 2026
·
Perspective
Success fee, no retainer. We are paid when you are. Plus senior access, protected disclosure, and pricing against real comparables.
Read the full article →
September 8, 2026
·
Perspective
The hidden cost of the fundraising treadmill is pulling the inventor off the science. A co-development partnership is built to keep them on it.
Read the full article →
September 4, 2026
·
Perspective
Upfront cash that costs no equity, a partner funding development, milestones and royalties, and you keep the company, the platform, and your stake.
Read the full article →
September 3, 2026
·
Perspective
For many platform companies the strongest next move is not another equity raise. It is a co-development partnership that pays cash up front and funds the program forward.
Read the full article →
September 2, 2026
·
Industry Watch
Lilly's ~$2.8B upfront acquisition of AtaiBeckley signals big pharma's early, high-conviction appetite for CNS. Where Modulus Biotech's AAV-REG3A platform sits.
Read the full article →
September 1, 2026
·
How We Work
A partner sees that the science works and is protected, not how to reproduce it, until the deal is real.
Read the full article →
August 28, 2026
·
Industry Watch
Between now and 2030, big pharma must replace billions in lost exclusivity; demand for de-risked science is rising.
Read the full article →
August 27, 2026
·
Science
Durable, infrequent dosing is a franchise, not a refill, and the market prices it that way.
Read the full article →
August 26, 2026
·
Science
REG3A (HIP-PAP) helps the liver protect and rebuild itself, and it is why the biology draws interest in liver disease.
Read the full article →
August 25, 2026
·
Deal Watch
For a decade, when a genetic-medicine platform shows durable delivery, the big acquirers move.
Read the full article →
August 21, 2026
·
Industry Watch
A single positive Phase 3 readout doubled a biotech in a day. De-risked, novel-modality data commands a premium.
Read the full article →
August 20, 2026
·
How We Work
For a scientist with a de-risked, proven molecule, the road to large pharma can be far shorter, and keep ownership intact.
Read the full article →
August 19, 2026
·
How We Work
A disciplined, competitive process, not the first term sheet, is how an inventor captures the value the science deserves.
Read the full article →
August 17, 2026
·
Major Press Release
THAC has retained Modulus Biotech to advance its first-in-class REG3A (HIP/PAP) therapeutic, ALF5755, toward co-development and licensing partnerships across five indication areas, beginning with the liver.
Read the full press release →
July 2, 2026
·
Industry Watch
On July 2, 2026, Microsoft announced Frontier Company, a $2.5 billion operating unit that will embed 6,000 industry and engineering experts inside customer organizations to co−design and deploy AI systems tied to measurable business outcomes.
Read the full announcement at Microsoft →
June 29, 2026
·
Pharma BD Watch
On June 29, 2026, French biopharma company Ipsen announced a $450 million acquisition of US-based Kartos Therapeutics — with up to $1.3 billion in additional milestone payments tied to regulatory and sales targets.
Read the full report at Investing.com →
May 26, 2026
·
Pharma BD Watch
Eli Lilly is back in infectious disease. On May 26, 2026, the company announced agreements to acquire Curevo (up to $1.5B, lead shingles vaccine amezosvatein), LimmaTech Biologics ($780M, bacterial pathogen vaccines), and Vaccine Company (up to $1.55B, in vivo nanoparticle platform with a Phase 1−ready Epstein−Barr Virus candidate) — collectively worth up to $3.83 billion.
Read the full report at FierceBiotech →